<DOC>
	<DOCNO>NCT00000700</DOCNO>
	<brief_summary>To examine dose zidovudine ( AZT ) use first placebo-controlled study AZT AIDS patient well low dose AZT order determine low dose result less harmful side effect still effective . Previous study show effectiveness AZT AIDS therapy . AZT effective test tube study vary dos . There need see low dos result effective therapy less harmful side effect .</brief_summary>
	<brief_title>A Multi-Center Clinical Trial To Evaluate Azidothymidine ( AZT ) Treatment Human Immunodeficiency Virus ( HIV ) Infection Patients With AIDS Post First Episode PCP</brief_title>
	<detailed_description>Previous study show effectiveness AZT AIDS therapy . AZT effective test tube study vary dos . There need see low dos result effective therapy less harmful side effect . Patients assign random one two treatment program : ( 1 ) 1 dose AZT give orally ( PO ) 6 dos per day ; ( 2 ) 2 dos AZT PO 4 week follow 1 dose PO remainder trial .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : All concomitant medication minimum record . Any approved medication use treat opportunistic infection . Dapsone may use Pneumocystis carinii pneumonia ( PCP ) . Pyrimethamine sulfadoxine may use toxoplasmosis . Ganciclovir cytomegalovirus may use maintenance . Prophylactic therapy PCP . Concurrent Treatment : Allowed : Local , limited radiation therapy isolate Kaposi 's sarcoma lesion provide total area &lt; 5 x 5 cm 6MeV electron beam 90 kV xray = &lt; 3000 rad total use . Patients must : HIV seropositivity confirm federally license ELISA test kit . Allowed : Malignancy past complete remission 1 year without therapy . Exclusion Criteria Coexisting Condition : Patients active opportunistic infection exclude . Concurrent Medication : Excluded : Aspirin regular basis beyond 72 hour without contact investigator . Cimetidine . Flurazepam . Indomethacin . Ranitidine . Probenecid . Patients follow exclude : Status postPneumocystis carinii pneumonia symptomatic visceral Kaposi 's sarcoma ( KS ) progression KS within month prior study entry . Other concurrent neoplasm basal cell carcinoma skin . Requiring blood transfusion &gt; per month . Last transfusion give within 7 day entry . Active substance abuse . Unwilling sign inform consent follow medical center enrol duration study followup necessary . Prior Medication : Excluded within 2 week study entry : Treatment acute Pneumocystis carinii pneumonia ( PCP ) . Excluded within 30 day study entry : Other antiretroviral agent , immunomodulating agent , corticosteroid . Prior Treatment : Excluded within 30 day study entry : Radiation therapy cytotoxic chemotherapy Kaposi 's sarcoma . Required : Patients must least 2 week post therapy status acute Pneumocystis carinii pneumonia ( PCP ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>United States</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>